HBeAg诱导的免疫激活和免疫抑制在慢性乙型肝炎中的作用

李欣阳; 涂正坤

doi:10.12449/JCH240525

HBeAg诱导的免疫激活和免疫抑制在慢性乙型肝炎中的作用

DOI: 10.12449/JCH240525

李欣阳,
涂正坤^, ,

吉林大学第一医院肿瘤免疫实验室，长春 130021

基金项目:

吉林省科技发展计划项目自然科学基金 (20190201245JC)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：李欣阳负责查阅文献，撰写文章；涂正坤负责拟定文章思路，指导撰写文章并最后定稿。

详细信息

通信作者:
涂正坤， tuzhengkun@hotmail.com （ORCID： 0000-0001-6803-2015）

计量
- 文章访问数: 218
- HTML全文浏览量: 69
- PDF下载量: 43
- 被引次数: 0
出版历程
- 收稿日期: 2024-01-25
- 录用日期: 2024-02-22
- 出版日期: 2024-05-25

Role of HBeAg-induced immune activition and immunosuppression in chronic hepatitis B

Xinyang LI,
Zhengkun TU^{,
,}

Laboratory of Tumor Immunology，The First Hospital of Jilin University，Changchun 130021，China

Research funding:

Jilin Province Science and Technology Development Plan Project Natural Science Foundation Project (20190201245JC)

More Information

Corresponding author: TU Zhengkun， tuzhengkun@hotmail.com （ORCID： 0000-0001-6803-2015）

摘要

摘要: HBV感染诱导的慢性乙型肝炎是导致肝硬化和肝癌的重要危险因素。半个世纪前，HBeAg在HBV感染者血清中首次被发现，尽管HBeAg并不参与HBV在肝细胞中的感染或复制，但其已被证实可干扰宿主先天性和适应性免疫反应，在慢性HBV感染的过程中发挥着重要的免疫激活和免疫抑制作用。HBV对于感染的肝细胞并没有细胞毒性，免疫应答介导的抗病毒作用和炎症反应决定HBV是否被清除或者诱导肝脏炎症相关疾病。因此，本文对HBeAg的形成及其在慢性HBV感染中引起的免疫激活和免疫抑制机制进行综述，重点论述HBeAg对先天免疫和适应性免疫细胞所引起的不同免疫效应，阐述了其诱导免疫反应的两面性，并探讨HBeAg在慢性HBV感染不同阶段间的转换作用。
- 乙型肝炎，慢性 /
- 乙型肝炎e抗原 /
- 免疫激活 /
- 免疫抑制
Abstract: Chronic hepatitis B induced by HBV infection is a significant risk factor leading to liver cirrhosis and liver cancer. Half a century ago， HBeAg was first discovered in the serum of HBV infected individuals， and although HBeAg does not participate in HBV infection or replication in hepatocytes， studies have shown that it can interfere with the innate and adaptive immune responses of the host and play an important role in immune activation and immunosuppression during chronic HBV infection. HBV has no cytotoxicity to the infected hepatocytes， and the antiviral action and inflammatory response mediated by immune response determine whether HBV is cleared or induces liver inflammation-related diseases. Therefore， this article reviews the formation of HBeAg and its immune activation and immunosuppression mechanisms in chronic HBV infection， with a focus on the different immune effects caused by HBeAg on innate immune and adaptive immune cells， and this article also elaborates on the dual role of HBeAg in inducing immune responses and explores the conversion role of HBeAg in different stages of chronic HBV infection.
- Hepatitis B， Chronic /
- Hepatitis B e Antigens /
- Immune Activation /
- Immune Suppressive

HTML全文

图 1 CHB感染各时期特征及免疫反应

注： ERK，细胞外调节蛋白激酶；pDC，浆细胞样树突状细胞；ROS，活性氧；TLR，Toll样受体；IFN，干扰素；IL，白细胞介素；NLRP3，NOD样受体蛋白3；MDSC，骨髓源性抑制细胞；IDO，吲哚胺2，3-双加氧酶；BAFF，B淋巴细胞激活因子；TNF，肿瘤坏死因子。

Figure 1. Characteristics and immune responses of different stages of CHB infection

下载: 全尺寸图片幻灯片

参考文献(45)

[1]	TANG LSY, COVERT E, WILSON E, et al. Chronic hepatitis B infection: A review[J]. JAMA, 2018, 319( 17): 1802- 1813. DOI: 10.1001/jama.2018.3795.
[2]	CHANG ML, LIAW YF. Hepatitis B flare in hepatitis B e antigen-negative patients: A complicated cascade of innate and adaptive immune responses[J]. Int J Mol Sci, 2022, 23( 3): 1552. DOI: 10.3390/ijms23031552.
[3]	MILICH DR. Is the function of the HBeAg really unknown?[J]. Hum Vaccin Immunother, 2019, 15( 9): 2187- 2191. DOI: 10.1080/21645515.2019.1607132.
[4]	PADARATH K, DEROUBAIX A, KRAMVIS A. The complex role of HBeAg and its precursors in the pathway to hepatocellular carcinoma[J]. Viruses, 2023, 15( 4): 857. DOI: 10.3390/v15040857.
[5]	XIE XY, LV HR, LIU CX, et al. HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis[J]. BMC Med, 2021, 19( 1): 247. DOI: 10.1186/s12916-021-02085-3.
[6]	TSUKUDA S, WATASHI K. Hepatitis B virus biology and life cycle[J]. Antiviral Res, 2020, 182: 104925. DOI: 10.1016/j.antiviral.2020.104925.
[7]	ITO K, KIM KH, LOK ASF, et al. Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme[J]. J Virol, 2009, 83( 8): 3507- 3517. DOI: 10.1128/JVI.02348-08.
[8]	KRAMVIS A, CHANG KM, DANDRI M, et al. A roadmap for serum biomarkers for hepatitis B virus: Current status and future outlook[J]. Nat Rev Gastroenterol Hepatol, 2022, 19( 11): 727- 745. DOI: 10.1038/s41575-022-00649-z.
[9]	TSAI KN, OU JH J. Hepatitis B virus e antigen and viral persistence[J]. Curr Opin Virol, 2021, 51: 158- 163. DOI: 10.1016/j.coviro.2021.10.003.
[10]	European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370- 398. DOI: 10.1016/j.jhep.2017.03.021.
[11]	European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57( 1): 167- 185. DOI: 10.1016/j.jhep.2012.02.010.
[12]	HSU YS, CHIEN RN, YEH CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B[J]. Hepatology, 2002, 35( 6): 1522- 1527. DOI: 10.1053/jhep.2002.33638.
[13]	NI YH, CHANG MH, CHEN PJ, et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion[J]. Gastroenterology, 2007, 132( 7): 2340- 2345. DOI: 10.1053/j.gastro.2007.03.111.
[14]	LIAW YF, LAU GKK, KAO JH, et al. Hepatitis B e antigen seroconversion: A critical event in chronic hepatitis B virus infection[J]. Dig Dis Sci, 2010, 55( 10): 2727- 2734. DOI: 10.1007/s10620-010-1179-4.
[15]	WANG WW, BIAN HJ, LI FF, et al. HBeAg induces the expression of macrophage miR-155 to accelerate liver injury via promoting production of inflammatory cytokines[J]. Cell Mol Life Sci, 2018, 75( 14): 2627- 2641. DOI: 10.1007/s00018-018-2753-8.
[16]	THOMSON AW, KNOLLE PA. Antigen-presenting cell function in the tolerogenic liver environment[J]. Nat Rev Immunol, 2010, 10( 11): 753- 766. DOI: 10.1038/nri2858.
[17]	LIU J, JIANG M, MA ZY, et al. TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8⁺ T cell immunity in vitro[J]. J Immunol, 2013, 191( 12): 6178- 6190. DOI: 10.4049/jimmunol.1301262.
[18]	XIE XH, LUO JZ, BROERING R, et al. HBeAg induces liver sinusoidal endothelial cell activation to promote intrahepatic CD8 T cell immunity and HBV clearance[J]. Cell Mol Immunol, 2021, 18( 11): 2572- 2574. DOI: 10.1038/s41423-021-00769-7.
[19]	YANG CL, LI N, WANG YW, et al. Serum levels of B-cell activating factor in chronic hepatitis B virus infection: Association with clinical diseases[J]. J Interferon Cytokine Res, 2014, 34( 10): 787- 794. DOI: 10.1089/jir.2014.0032.
[20]	LI HJ, ZHAI NC, SONG HX, et al. The role of immune cells in chronic HBV infection[J]. J Clin Transl Hepatol, 2015, 3( 4): 277- 283. DOI: 10.14218/JCTH.2015.00026.
[21]	LU BR, ZHANG BC, WANG LC, et al. Hepatitis B virus e antigen regulates monocyte function and promotes B lymphocyte activation[J]. Viral Immunol, 2017, 30( 1): 35- 44. DOI: 10.1089/vim.2016.0113.
[22]	MÖCKEL T, BASTA F, WEINMANN-MENKE J, et al. B cell activating factor(BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus(SLE)[J]. Autoimmun Rev, 2021, 20( 2): 102736. DOI: 10.1016/j.autrev.2020.102736.
[23]	WANG L, ZENG XQ, WANG ZD, et al. Recent advances in understanding T cell activation and exhaustion during HBV infection[J]. Virol Sin, 2023, 38( 6): 851- 859. DOI: 10.1016/j.virs.2023.10.007.
[24]	JORGOVANOVIC D, SONG MJ, WANG LP, et al. Roles of IFN-γ in tumor progression and regression: A review[J]. Biomark Res, 2020, 8: 49. DOI: 10.1186/s40364-020-00228-x.
[25]	CHISARI FV, ISOGAWA M, WIELAND SF. Pathogenesis of hepatitis B virus infection[J]. Pathol Biol(Paris), 2010, 58( 4): 258- 266. DOI: 10.1016/j.patbio.2009.11.001.
[26]	XIE XH, LUO JZ, ZHU D, et al. HBeAg is indispensable for inducing liver sinusoidal endothelial cell activation by hepatitis B virus[J]. Front Cell Infect Microbiol, 2022, 12: 797915. DOI: 10.3389/fcimb.2022.797915.
[27]	CHEN WJ, BIAN HJ, XIE XY, et al. Negative feedback loop of ERK/CREB/miR-212-3p inhibits HBeAg-induced macrophage activation[J]. J Cell Mol Med, 2020, 24( 18): 10935- 10945. DOI: 10.1111/jcmm.15723.
[28]	TIAN YJ, KUO CF, AKBARI O, et al. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission[J]. Immunity, 2016, 44( 5): 1204- 1214. DOI: 10.1016/j.immuni.2016.04.008.
[29]	HATIPOGLU I, ERCAN D, ACILAN C, et al. Hepatitis B virus e antigen(HBeAg) may have a negative effect on dendritic cell generation[J]. Immunobiology, 2014, 219( 12): 944- 949. DOI: 10.1016/j.imbio.2014.07.020.
[30]	SIOUD M, FLØISAND Y. TLR agonists induce the differentiation of human bone marrow CD34⁺ progenitors into CD11c⁺ CD80/86⁺ DC capable of inducing a Th1-type response[J]. Eur J Immunol, 2007, 37( 10): 2834- 2846. DOI: 10.1002/eji.200737112.
[31]	WANG FC, SONG MY, HU YH, et al. The relation of the frequency and functional molecules expression on plasmacytoid dendritic cells to postpartum hepatitis in women with HBeAg-positive chronic hepatitis B virus infection[J]. Front Immunol, 2022, 13: 1062123. DOI: 10.3389/fimmu.2022.1062123.
[32]	LEU CM, LU YC, PENG WL, et al. The hepatitis B virus e antigen suppresses the respiratory burst and mobility of human monocytes and neutrophils[J]. Immunobiology, 2014, 219( 11): 880- 887. DOI: 10.1016/j.imbio.2014.07.008.
[33]	YANG SS, LIAN GJ. ROS and diseases: Role in metabolism and energy supply[J]. Mol Cell Biochem, 2020, 467( 1-2): 1- 12. DOI: 10.1007/s11010-019-03667-9.
[34]	YANG FF, YU XP, ZHOU CL, et al. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection[J]. PLoS Pathog, 2019, 15( 4): e1007690. DOI: 10.1371/journal.ppat.1007690.
[35]	RACANELLI V, REHERMANN B. The liver as an immunological organ[J]. Hepatology, 2006, 43(2 Suppl 1): S54- S62. DOI: 10.1002/hep.21060.
[36]	SUN C, FU BQ, GAO YF, et al. TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence[J]. PLoS Pathog, 2012, 8( 3): e1002594. DOI: 10.1371/journal.ppat.1002594.
[37]	MA QQ, DONG XY, LIU SY, et al. Hepatitis B e antigen induces NKG2A⁺ natural killer cell dysfunction via regulatory T cell-derived interleukin 10 in chronic hepatitis B virus infection[J]. Front Cell Dev Biol, 2020, 8: 421. DOI: 10.3389/fcell.2020.00421.
[38]	JEGASKANDA S, AHN SH, SKINNER N, et al. Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen[J]. J Virol, 2014, 88( 18): 10412- 10420. DOI: 10.1128/JVI.00111-14.
[39]	FERRANDO-MARTINEZ S, HUANG K, BENNETT AS, et al. HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection[J]. JHEP Rep, 2019, 1( 3): 170- 178. DOI: 10.1016/j.jhepr.2019.06.001.
[40]	PARKER KH, BEURY DW, OSTRAND-ROSENBERG S. Myeloid-derived suppressor cells: Critical cells driving immune suppression in the tumor microenvironment[J]. Adv Cancer Res, 2015, 128: 95- 139. DOI: 10.1016/bs.acr.2015.04.002.
[41]	MUNN DH, MELLOR AL. IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance[J]. Trends Immunol, 2016, 37( 3): 193- 207. DOI: 10.1016/j.it.2016.01.002.
[42]	KRAMVIS A, KOSTAKI EG, HATZAKIS A, et al. Immunomodulatory function of HBeAg related to short-sighted evolution, transmissibility, and clinical manifestation of hepatitis B virus[J]. Front Microbiol, 2018, 9: 2521. DOI: 10.3389/fmicb.2018.02521.
[43]	LEE WM, KING WC, JANSSEN HLA, et al. Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study[J]. J Viral Hepat, 2021, 28( 11): 1526- 1538. DOI: 10.1111/jvh.13591.
[44]	TSAI SL, CHEN PJ, LAI MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion[J]. J Clin Invest, 1992, 89( 1): 87- 96. DOI: 10.1172/JCI115590.
[45]	YANG HC, KAO JH. Revisiting the natural history of chronic HBV infection[J]. Curr Hepatol Rep, 2016, 15( 3): 141- 149. DOI: 10.1007/s11901-016-0304-z.